Original language | English |
---|---|
Pages (from-to) | 479-481 |
Number of pages | 3 |
Journal | Proteins: Structure, Function and Bioinformatics |
Volume | 55 |
Issue number | 2 |
DOIs | |
State | Published - 1 May 2004 |
Bibliographical note
Funding Information:We thank the participants of Clue I and Clue II and appreciate the continued efforts of the staff at the Johns Hopkins George W Comstock Center for Public Health Research and Prevention in the conduct of the Clue Cohort Studies. Cancer incidence data were provided by the Maryland Cancer Registry, Center for Cancer Surveillance and Control, Maryland Department of Health, 201 W. Preston Street, Room 400, Baltimore, MD 21201, https://phpa.health.maryland.gov/cancer/Pages/mcr_home.aspx, 410-767-4055. The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at: http://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Long%20List.pdf. The Nord-Tr?ndelag Health Study (The HUNT Study) is collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology), Nord-Tr?ndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. The study has used data from the Cancer Registry of Norway. The interpretation and reporting of these data are the sole responsibility of the authors, and no endorsement by the Cancer Registry of Norway is intended nor should be inferred. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle G?n?rale de l'Education Nationale, Institut National de la Sant? et de la Recherche M?dicale (INSERM) (France); German Cancer Aid, German Cancer Research Centre (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); National Institute for Public Health and the Environment, Bilthoven, (The Netherlands) for their contribution to data collection; Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andaluc?a, Asturias, Basque Country, Murcia (no. 6236) and the Catalan Institute of Oncology (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Sk?ne and V?sterbotten (Sweden); Cancer Research UK (14136 to K.T. Khaw, N.J. Wareham; C570/A16491 to R.C. Travis and C8221/A19170 to T. Key (EPIC-Oxford), Medical Research Council (1000143 to K.T. Khaw, N.J. Wareham, MR/M012190/1 to T. Key (EPIC-Oxford)) (United Kingdom). HPVC3 was funded by a grant from the US National Cancer Institute (grant: 5U01CA195603-02), with additional support from the intramural program of the Division of Cancer Epidemiology and Genetics, US NCI. We acknowledge the State of Maryland, the Maryland Cigarette Restitution Fund, and the National Program of Cancer Registries of the Centers for Disease Control and Prevention for the funds that support the collection and availability of the cancer registry data. MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants (209057 and 396414) and by infrastructure provided by Cancer Council Victoria. Cases were ascertained through the Victorian Cancer Registry (VCR) and the Australian Cancer Database (Australian Institute of Health and Welfare). Involvement of the Women's Health Initiative (WHI) collaborators was supported in part by National Cancer Institute P30 grants to the Roswell Park Comprehensive Cancer Institute (CA016056), and Einstein Cancer Research Center (CA013330). The WHI program is funded by the National Heart, Lung, and Blood Institute, NIH, U.S. Department of Health and Human Services through contracts (HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C). US National Cancer Institute5U01CA195603-02, Division of Cancer Epidemiology, the State of Maryland, the Maryland Cigarette Restitution Fund, National Program of Cancer Registries of the Centers for Disease Control and Prevention, VicHealth and Cancer Council Victoria, Australian NHMRC209057396414, Cancer Council Victoria, Victorian Cancer Registry, VCR, Australian Cancer Database, Australian Institute of Health and Welfare, Women's Health Initiative, WHI, National Cancer Institute P30, Roswell Park Comprehensive Cancer InstituteCA016056, Einstein Cancer Research CenterCA013330, WHI, National Heart, Lung, and Blood Institute, NIH, U.S. Department of Health and Human ServicesHHSN268201600018CHHSN268201600001CHHSN268201600002CHHSN268201600003CHHSN268201600004C, The authors have declared no conflicts of interest.
Funding Information:
HPVC3 was funded by a grant from the US National Cancer Institute (grant: 5U01CA195603-02), with additional support from the intramural program of the Division of Cancer Epidemiology and Genetics, US NCI. We acknowledge the State of Maryland, the Maryland Cigarette Restitution Fund, and the National Program of Cancer Registries of the Centers for Disease Control and Prevention for the funds that support the collection and availability of the cancer registry data. MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants (209057 and 396414) and by infrastructure provided by Cancer Council Victoria. Cases were ascertained through the Victorian Cancer Registry (VCR) and the Australian Cancer Database (Australian Institute of Health and Welfare). Involvement of the Women’s Health Initiative (WHI) collaborators was supported in part by National Cancer Institute P30 grants to the Roswell Park Comprehensive Cancer Institute (CA016056), and Einstein Cancer Research Center (CA013330). The WHI program is funded by the National Heart, Lung, and Blood Institute, NIH, U.S. Department of Health and Human Services through contracts (HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C).
Funding Information:
The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Centre (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); National Institute for Public Health and the Environment, Bilthoven, (The Netherlands) for their contribution to data collection; Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia (no. 6236) and the Catalan Institute of Oncology (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to K.T. Khaw, N.J. Wareham; C570/A16491 to R.C. Travis and C8221/A19170 to T. Key (EPIC-Oxford), Medical Research Council (1000143 to K.T. Khaw, N.J. Wareham, MR/M012190/1 to T. Key (EPIC-Oxford)) (United Kingdom).